Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gazzard

Showing results (101-110 of 206) with videos related to

Pageof 21
Sort By:
Antiviral Therapy|June 26, 2014
Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapyLaura Waters, Akil Jackson, Laura Else, et al.
AIDS Research and Human Retroviruses|March 18, 2003
Thymic output during initial highly active antiretroviral therapy (HAART) and during HAART supplementation with interleukin 2 and/or with HIV type 1 immunogen (Remune)Jeffrey Pido-Lopez, Catherine Burton, Gareth Hardy, et al.
Plos One|May 13, 2009
Transient nature of long-term nonprogression and broad virus-specific proliferative T-cell responses with sustained thymic output in HIV-1 controllersSamantha J Westrop, Nadeem A Qazi, Jeffrey Pido-Lopez, et al.
AIDS (London, England)|June 25, 2009
The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcomaMark Bower, Justin Weir, Nicholas Francis, et al.
Journal of Clinical Gastroenterology|September 12, 2009
A meta-analysis of transient elastography for the detection of hepatic fibrosisJustin Stebbing, Lavanta Farouk, George Panos, et al.
The Journal of Antimicrobial Chemotherapy|March 12, 2011
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteersAkil Jackson, Antonio D'Avolio, Victoria Watson, et al.
International Journal of Cancer|December 30, 2003
The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcomaJustin Stebbing, Simon Portsmouth, Mark Nelson, et al.
AIDS (London, England)|April 20, 2004
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?Alan Winston, Anton Pozniak, Nicola Smith, et al.
AIDS Research and Human Retroviruses|August 17, 2006
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir dosesMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
Blood|May 17, 2003
Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptorJustin Stebbing, Brian Gazzard, Simon Portsmouth, et al.
Pageof 21

Showing results (101-110 of 206) with videos related to

Sort By:
Pageof 21
Antiviral Therapy|June 26, 2014
Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapyLaura Waters, Akil Jackson, Laura Else, et al.
AIDS Research and Human Retroviruses|March 18, 2003
Thymic output during initial highly active antiretroviral therapy (HAART) and during HAART supplementation with interleukin 2 and/or with HIV type 1 immunogen (Remune)Jeffrey Pido-Lopez, Catherine Burton, Gareth Hardy, et al.
Plos One|May 13, 2009
Transient nature of long-term nonprogression and broad virus-specific proliferative T-cell responses with sustained thymic output in HIV-1 controllersSamantha J Westrop, Nadeem A Qazi, Jeffrey Pido-Lopez, et al.
AIDS (London, England)|June 25, 2009
The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcomaMark Bower, Justin Weir, Nicholas Francis, et al.
Journal of Clinical Gastroenterology|September 12, 2009
A meta-analysis of transient elastography for the detection of hepatic fibrosisJustin Stebbing, Lavanta Farouk, George Panos, et al.
The Journal of Antimicrobial Chemotherapy|March 12, 2011
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteersAkil Jackson, Antonio D'Avolio, Victoria Watson, et al.
International Journal of Cancer|December 30, 2003
The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcomaJustin Stebbing, Simon Portsmouth, Mark Nelson, et al.
AIDS (London, England)|April 20, 2004
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?Alan Winston, Anton Pozniak, Nicola Smith, et al.
AIDS Research and Human Retroviruses|August 17, 2006
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir dosesMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
Blood|May 17, 2003
Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptorJustin Stebbing, Brian Gazzard, Simon Portsmouth, et al.
Pageof 21